Shopping Cart 0
Cart Subtotal
USD 0

Antisense Therapeutics Ltd (ANP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of cancer treatment, respiratory diseases, immunology disorders and rare diseases. Antisense Therapeutics's development pipeline comprises of ATL1103 which blocks GHr production and lowers blood IGF-I levels and is a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis and also pre-clinical development stage for the treatment of asthma as an inhalation; and ATL1101 which is being investigated for the potential treatment for prostate cancer. Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Antisense Therapeutics Ltd (ANP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10

Licensing Agreements 12

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12

Equity Offering 14

Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14

Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15

Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17

Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19

Antisense Therapeutic Completes Rights Issue Of Common Stock For USD 0.6 Million 21

Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For USD 2.04 Million 22

Antisense Therapeutics Ltd-Key Competitors 23

Antisense Therapeutics Ltd-Key Employees 24

Antisense Therapeutics Ltd-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Product News 26

10/30/2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting 26

Jun 16, 2017: Antisense Therapeutics: Positive effects seen with ATL1102 on Multiple Sclerosis Black Hole brain lesions 27

Product Approvals 28

Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA 28

Apr 24, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Submission 29

Clinical Trials 30

Feb 28, 2018: Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy 30

Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update 31

Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update 32

Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102 33

Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102 34

Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis 35

Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 36

Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis Black Hole brain lesions 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12

Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14

Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15

Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17

Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19

Antisense Therapeutic Completes Rights Issue Of Common Stock For USD 0.6 Million 21

Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For USD 2.04 Million 22

Antisense Therapeutics Ltd, Key Competitors 23

Antisense Therapeutics Ltd, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Antisense Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Antisense Therapeutics Ltd (Antisense Therapeutics) is clinical staged biopharmaceutical company which focuses on the discovery, development and commercialization of second generation antisense pharmaceuticals for various medical conditions that have large unmet medical needs. It focuses on the development of antisense drugs in the areas of cancer treatment, respiratory diseases, immunology disorders and rare diseases. Antisense Therapeutics's development pipeline comprises of ATL1103 which blocks GHr production and lowers blood IGF-I levels and is a potential treatment for growth hormone disorders such as Acromegaly; ATL1102 (injection), which reduces brain lesions is being development for the treatment of multiple sclerosis and also pre-clinical development stage for the treatment of asthma as an inhalation; and ATL1101 which is being investigated for the potential treatment for prostate cancer. Antisense Therapeutics is headquartered in Toorak, Victoria, Australia.

Antisense Therapeutics Ltd (ANP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10

Licensing Agreements 12

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12

Equity Offering 14

Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14

Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15

Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17

Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19

Antisense Therapeutic Completes Rights Issue Of Common Stock For USD 0.6 Million 21

Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For USD 2.04 Million 22

Antisense Therapeutics Ltd-Key Competitors 23

Antisense Therapeutics Ltd-Key Employees 24

Antisense Therapeutics Ltd-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Product News 26

10/30/2017: ATL1102 'Black Hole' MS data presented at the 7th Joint ECTRIMS-ACTRIMS Meeting 26

Jun 16, 2017: Antisense Therapeutics: Positive effects seen with ATL1102 on Multiple Sclerosis Black Hole brain lesions 27

Product Approvals 28

Jun 26, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Application Submitted to the FDA 28

Apr 24, 2017: ATL1102 for Multiple Sclerosis-Phase IIb Investigational New Drug Submission 29

Clinical Trials 30

Feb 28, 2018: Approval received for Phase II trial of ATL1102 in Duchenne Muscular Dystrophy 30

Nov 21, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Status Update 31

Oct 17, 2017: ATL1102 for Multiple Sclerosis and Duchenne Muscular Dystrophy Update 32

Oct 02, 2017: Antisense Therapeutics Provides Update on Multiple Sclerosis Drug Candidate ATL1102 33

Sep 12, 2017: Antisense Therapeutics Announces Update on ATL1102 34

Jul 27, 2017: Antisense Therapeutics Provides Phase IIb Trial Update on ATL1102 for Multiple Sclerosis 35

Jun 26, 2017: Antisense Therapeutics to Enter Clinical Development in Duchenne Muscular Dystrophy 36

Jun 16, 2017: Positive effects seen with ATL1102 on Multiple Sclerosis Black Hole brain lesions 38

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Antisense Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Antisense Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Antisense Therapeutics Forms Joint Venture With Tianjin International Joint Academy 10

Cortendo Enters into Licensing Agreement with Antisense Therapeutics 12

Antisense Therapeutics Raises USD3.4 Million in Rights Offering of Shares 14

Antisense Therapeutics Raises USD0.4 Million in Institutional Private Placement of Shares 15

Antisense Therapeutics Raises USD0.8 Million in Private Placement of Shares 17

Antisense Therapeutics to Raise USD1.3 Million in Private Placement of Shares 19

Antisense Therapeutic Completes Rights Issue Of Common Stock For USD 0.6 Million 21

Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For USD 2.04 Million 22

Antisense Therapeutics Ltd, Key Competitors 23

Antisense Therapeutics Ltd, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Antisense Therapeutics Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.